Pharmaceutical Developer Champions Strict Science Over Commercial Cannabis in Medicare Dispute
New York, Monday, 25 May 2026.
After a judge dismissed their Medicare lawsuit without reviewing the science, MMJ International rejected anti-marijuana labels, prioritizing FDA-regulated chemistry and patient safety over commercial cannabis markets.
The Legal Dismissal and MMJ’s Response
On May 23, 2026, US District Court Judge Trevor N. McFadden dismissed a lawsuit challenging the Centers for Medicare & Medicaid Services’ (CMS) Substance Access Beneficiary Engagement Incentive (BEI) program [3]. The program controversially allows Medicare beneficiaries to consult with healthcare providers and receive up to $500 annually in hemp products [3]. The lawsuit, brought forward by clinical-stage pharmaceutical developer MMJ International Holdings alongside 11 marijuana opposition groups, was thrown out because the plaintiffs failed to demonstrate they were directly injured by the program [3]. Ultimately, the dismissal was rooted in procedural standing rather than an evaluation of the program’s safety or federal legality [1][3].
Committing to the FDA Botanical Pathway
MMJ’s push for stringent oversight is underpinned by its own extensive operational history within federal regulatory frameworks [GPT]. For nearly eight years, the company has adhered to strict federal rules, securing FDA Investigational New Drug (IND) applications and an Orphan Drug Designation [2]. Furthermore, MMJ has obtained a Drug Enforcement Administration (DEA) Schedule I analytical laboratory registration, positioning itself to study and develop cannabinoid-based medicines strictly through the FDA’s botanical drug development pathway [1][2].
Navigating Regulatory Contradictions
The core of MMJ’s frustration lies in what it views as contradictory federal policies regarding cannabinoid access [1]. Boise publicly questioned why the federal government is using Medicare to facilitate access to commercial hemp-derived cannabinoid products while simultaneously preparing to enforce stricter federal restrictions [1]. Specifically, Section 781 of Public Law 119-37, which imposes federal limits on hemp-derived cannabinoid products, is slated to take effect later this year on November 12, 2026 [1]. This looming deadline creates a paradoxical regulatory environment where seniors are subsidized for products that face impending federal crackdowns [1].
A Broader Call for Patient Safety
The friction between regulated clinical research and commercial cannabis use is evident across multiple federal agencies in May 2026 [GPT]. On May 18, 2026, the US Army issued statements indicating that cannabinoids compromise military readiness, and the following day, the Department of Transportation affirmed that federal drug testing rules for workers remain unchanged despite ongoing rescheduling discussions [4]. Additionally, emerging research has highlighted unmonitored risks in commercial markets, drawing attention to cannabis-susceptible molds that currently lack state testing requirements [4].